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Abstract
The purpose of this paper is to discuss the intellectual property（IP）strategies em-
ployed by various pharmaceutical companies, and to examine how each strategy improves
the research and development profitability. Additionally, alternative IP strategies will be dis-
cussed. A highlight of the paper will be the a description advancing drug development pipe-
lines and how they contribute to large pharmaceutical companies research improvement
and development profitability. A specific focus will be on the IP strategies of the leading
pharmaceutical companies, which include: Takeda Pharmaceutical Company Limited, Eisai
Co. Ltd., Daiichi Sankyo Company Limited, Astellas Pharma Inc., Pfizer Inc., Johnson &
Johnson Inc., Novartis International AG, Roche Holding AG and Gilead Sciences Inc.
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＊ The paper is based on doctoral dissertation,“ The Intellectual Property Strategies of Large Pharmaceutical
Companies: the Perspective of Improving R&D Profitability”.
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１. Introduction
Pharmaceutical companies（hereafter, PCs）are exposed to a number of industry
specific-factors that can significantly influence their financial performance. These factors in-
clude, but are not limited to, research and development（R&D）productivity, the loss or ex-
piration of intellectual property rights, the regulatory standards for new drug approval, and
healthcare legislation.
A challenge PCs have been exposed to since the mid-１９９０s is a decline in R&D pro-
ductivity, despite sustained increases in R&D expenditure. The issue, however, has not yet
been resolved.
In reviewing representative literatures that focused on scale advantage, propose
that scale advantage has positive advantages on R&D profitability. Previous research stud-
ies have indicated that the greater the R&D expenditure, the greater the number of R&D
products（e.g., Langowitz and Graves, １９９２; Henderson & Cockburn, １９９６; Anagnostopoulou
& Levis, ２００８）. Henderson & Cockburn（１９９６）suggested that with larger R&D scale and
scope, higher returns will be generated due to spillover advantage and internal spillover of
knowledge. Anagnostopoulou & Levis（２００８）considered that R&D intensity（referring to
the scale of expenditure and the scope of research projects）improves persistence in excess
stock return. Moreover, Ciftci & Cready（２０１１）studied how R&D-related earnings perform-
ance, market returns and earnings variability depend upon firm size and R&D intensity.
They found a positive association between these returns and R&D intensity. This was at-
tributed to the economy of scope as well as the scale of R&D, that is, greater R&D efforts
were more productive and less uncertain. Therefore, it is probable that reducing R&D inten-
sity would decrease a firm’s future returns and profitability. Indeed, pharma companies
have worked in this way in the past decades. They have invested much money in many R&
D projects and have greatly increased output. However, because of reforms to the regula-
tions for drug approval, which entail much more clinical testing data than before, drug ap-
proval became difficult and the cost of R&D increased１. Thus, pharma companies’profits
have diminished due to a decrease in the number of drugs being approved and increases in
１ Under these circumstances, major mergers and acquisitions（M&A）actions have been conducted since
the mid-１９９０s. The objective of M&A in this period have been to address the scale of R&D expending and to
obtain the potential products.
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Table １ The features of the main researchs
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Recently, the issues of how to enable greater R&D efficiency and shorten the R&D
period became an important challenge for PCs. More recent research has revealed the in-
dustry-specific difference that arose subsequent to the strengthening of medical approval
regulation, and proposed that utilization of external resource, and rationalization of portfolio
would improve profitability from the cost reduction perspective, as utilizing external re-
source has the following strengths: cost reduction, reduction of the time-to-market, and risk
distribution（e.g., Danzon et al., ２００５; Mait & Raghavendra, ２００７; Lowman et al., ２０１２; Rafols
et al., ２０１４; Paul et al., ２０１０）. Utilizing external resource, however, can not only reduce R&D
costs and spread risk, but can help a PC concentrate its resources on developing core yields.
In order to access the external resource, PCs not only conduct M&A２, but also form strate-
gic alliances with other companies whose have advanced technologies in the specific field.
The alliance occurs through licensing-in, collaborative research, and out-sourcing the clinical
development process（Danzon et al., ２００５; Mait & Raghavendra, ２００７; Kneller, ２０１０; Howells
et al.,２００８; Howells et al.,２０１２; Lin et al.,２０１２）.
２ The objective of M&A recently has been to obtain the external technologies to fulfil R&D gaps.
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In spite of the growing literatures on how to improve R&D profitability, the issue
of a decline in R&D profitability has not been resolved yet. To summarize, the paper ex-
plores the issue at corporate level and attempts to complement existing research by examin-
ing the leading pharmaceutical companies in the world, mainly through discussion of the IP
strategies employed by those companies.
How is IP strategy defined？ The definition of IP strategy varies greatly by indus-
try. This paper defines IP strategy as it is related to the IP life cycle（that is, creation→pro-
tection→exploitation→creation）, as the cost and return will be altered with changing IP
status. The main focus will be on how to create or obtain IP and what role this plays in the
enrichment of drug discovery pipelines. IP can be obtained in two ways: created in-house, or
brought in from an external resource.
The remainder of this paper is structured as follows. In the second section, we
highlight the characteristics of pharmaceutical companies. In the third section, we analysis
and classify the IP strategies taken by companies. On this basis, the fourth section examines
the management policy, which influences and determines the way the IP strategies are de-
veloped. The last section summarizes the findings of this paper.
２. Characteristics of Leading Pharmaceutical Companies
２.１ Complexity in R&D
Drug discovery and development is time-consuming, expensive and unpredictable.
After the process of New Molecular Entities（NMEs）research, PCs have to screen the new
chemical entities they have discovered, conduct pre-clinical trials, and conduct clinical trials
to provide data on the drug’s safety and efficacy to support the evaluation of its overall
benefit-risk profile for a particular patient population. In addition, after a product has been
approved and launched, PCs continue to monitor the product’s safety as long as it is avail-
able to patients, and post-marketing trials may be conducted, including trials requested by
regulators. These process require higher R&D cost than other industries and account for ap-
proximately１５% of net sales. Even though pharmaceuticals require huge R&D expenditure,
the number of approved New Molecular Entities has decreased since the１９９０s（as shown in
Table２３）. This tendency is considered to represent declining R&D productivity. Since drugs
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Table ２ The R&D expenditures of the members of JPMA, PhRMA and EFPIA, and
the number of approved NMEs by FDA
Source: based on Website of JPMA, PhRMA, EFPIA and FDA.
are the source of income, declining R&D productivity will diminish the firm’s future sales
and revenues. The paper therefore considers R&D productivity as R&D profitability.
２.２ Decline in R&D profitability
In spite of increasing R&D expending, however, the R&D profitability is continuing
to decline. The issue of declining R&D profitability is due to R&D productivity, as the out-
put of R&D is the driver of sales. The reasons for declining R&D productivity are: １）Re-
formed regulations on drug approval, which entail much more clinical testing data than be-
fore, and which mean PCs must spend more time conducting clinical testing in the clinical
trials stage, leading to more cost. ２）The declining number of NMEs, the origin of new
drugs, which makes it more difficult for PCs to conduct R&D.
３ Table１ shows that the number of approved New Molecular Entities has increased since ２０１１. This is be-
cause the figures from２０１１included the number of BLA（Biologics License Application）, in fact, the number
of approved New Molecular Entities continues to decline.
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As shown in Figure１and Figure２, the profitability of leading pharmaceutical com-
panies has dramatically fallen short of their expectations. R&D profitability means return on
R&D investment, indicates how effective of R&D activity generate the profit with R&D in-
vestment.
The paper presents a focus on“return on investment”, because we consider that
operating income is produced by R&D activities. Therefore, the index on the profitability of
R&D is the ratio of operating income to R&D investment（R&D expenditure）. This is an in-
dex which measures how much profit is yielded from invested capital（R&D expenditure）.
The formula for R&D profitability is shown as follows:
R&D profitability＝operating incomeR&D expenditure
Regarding the data on operating income and R&D expenditure, it is not appropri-
ate to use operating income and R&D expenditure data from the same year. This is because
R&D activities would create some outputs, and the benefit of these outputs would be experi-
enced some years later. Thus, it is difficult to determine the current profits from R&D in-
vestment except for profits from market reaction. How long, in years, would the time lag be
between R&D expenditure and realization of its outcomes？ In this paper, we consider that
time lag as five years. Odagiri and Murakami（１９９２）estimated the lag to be six to eight
years. Based on Odagiri and Murakami（１９９２）, Hashimoto and Haneda（２００８）used eight
years, matching input data of a given year with output data from eight years later. Consid-
ering that the average time for R&D activity in the pharmaceutical industry is ７―１３ years,
we here match R&D expenditure data of a given year with operating income data from five
years later.
We use five-year cumulative data to measure R&D profitability for the following
two reasons: １）the average time for the R&D activity process in the pharmaceutical indus-
try is７―１３years, i.e., PCs should continue to invest in R&D activities（１ R&D project）dur-
ing this period.２）Generally, PCs apply for a patent to protect the knowledge they generate.
Though the patent often gives pharma companies a monopolistic control over new drugs for
２０ years, practically, a patent only benefits them for ８―１１ years. Because PCs apply for a
patent from the basic research stage, and as mentioned before, the R&D activity process re-
quires on average７～１３years, i.e., after drug approval, the output of R&D expenditure gen-
erates a benefit for７～１３years. For these reasons, we use five-year cumulative data includ-
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Figure １ R&D profitability of Japanese pharmaceutical companies
Source: Based on annual reports of each company mentioned above.
Figure ２ R&D profitability of American and European pharmaceutical companies
Source: Based on annual reports of each company mentioned above.
ing R&D expenditure and operating income.
３. Intellectual property strategies of pharmaceutical companies
This section examines the IP strategies of the leading pharmaceutical companies,
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which include: Takeda Pharmaceutical Company Limited, Eisai Co. Ltd., Daiichi Sankyo
Company Limited, Astellas Pharma Inc., Pfizer Inc., Johnson & Johnson Inc., Novartis Inter-
national AG, Roche Holding AG and Gilead Sciences Inc. The results of this examination are
as follows. Compared to other PCs, which have a long history in the pharmaceutical indus-
try, Gilead Sciences is a young company as it was incorporated in １９８７. Gilead Sciences,
however, has achieved great success by its IP strategy, hence; it was selected as the re-
search target.
３.１ Profit expansion perspective
Reorganizing the R&D portfolio into two patterns: a diversified business（such as
Pfizer, J&J, Eisai, Daiichi Sankyo, Merck）, that has a mix of diagnostics, generics, medical de-
vices, innovative drug, animal health business under a single umbrella organization; and spe-
cialized business（such as Gilead, Astellas, Takeda, Roche, Novartis）, which is focused pri-
marily on innovative drugs.
Some companies focus on diverse fields, with the aim of expanding sales to offset
the declines in mature fields. They run multiple businesses based on existing resources to
expand the sales. Novartis, for instance, which takes a diversification strategy, has devel-
oped a generics division, in order to expand the sales scales.
Other companies take concerted action on specialized businesses, which is intended
to strengthen the main field by concentrating the business resources on the main field.
In order to improve profitability, PCs have adjusted the research focus with a
profit-generating perspective although this activity may not be profitable in the short-term４.
The research focus of PCs was adjusted as follows: from low-molecular to biopharmaceuti-
cals, add function of established products, increasing attention to the areas of unmet medical
needs field５.
４ Additionally, the reason for adjusting the focus to the areas of unmet medical needs field are not only to
do with profit, but to do with social responsibility. As unmet medical needs field is a field which with limited
commercial market（in terms of small market size）, PCs did not conduct R&D in this field in the past
（Yamada, ２００５:３１）. Recently, however, with the increasing focus on the ESG（Environment, Social, Govern-
ance）issue, PCs need to integrate social consideration into core business operation and strategy to improve
enterprise value.
５ The disease areas including urology, immunology and inflammatory, central nervous system and pain, dia-
betes, infectious disease, oncology, have low patient satisfaction.
―― 経 営 論 集 ――２６２
／■修校了／１２－２８５／本文／ＡＺ２８５Ｐ 2018.03.13 16.49.10 Page 288
















- add function of
established
products
























３.２ Cost reduction perspective
They take partnership with potential companies, which have skills they lack, in or-
der to bring together experts and knowledge from different fields, through the methods of
M&A, licensing-in, collaborative research, and clinical process out-sourcing. PCs therefore
utilize the external resources outside the company with the aims of modifying process,
shortening the R&D duration, and improving their core capacity.
Regarding utilization of external resources, however, there are a big differences
among Japanese companies, American companies, and European companies. That is, Ameri-
can and European companies utilize the external resource actively, whereas Japanese com-
panies do not utilise them much.
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４. Different strategies taken to management policy
The strategies shown in Table３reveal some common view except reorganization of
the portfolio which is classified into specialization and diversification. The paper defines di-
versification as a pattern that diversified companies’portfolio based on chemical technology.
Why do PCs choose different strategies？ They take different strategies due to
their management policy, so it is difficult to say whether specialization or diversification is
right for PCs６. Under the pressure of increasing R&D cost, PCs reform their portfolio in or-
der to better allocate their resources, through selecting and concentrating their business
segments. They adopt specialization strategies aimed at further improving the effectiveness
and efficiency of their R&D activities. On the other hand, other companies adopt diversifica-
tion strategies aimed to expand the sales scales to offset a decline in their main field,
thereby recurring group’s profitability.
４.１ Strengthen the core competence by specialization
PCs focused on the innovative medicine business, concentrate their resources on
the given field to optimize the R&D activities in resource-setting, therefore strengthen and
maintain the position as the global category leader in the given areas. They concentrate on
a core business, and rationalize mergers and growth strategies, as well as divestitures and
restructuring（e.g., Gilead）. At the same time, when there are outstanding capabilities out-
sider the company, PCs will proactively form partnerships. By combining optimal capabili-
ties, both internal and external, thereby enhance their productivity to maximize value crea-
tion capabilities.
４.２Offset a declines in sales by diversification
PCs can face the a decline in core operating income, mainly due to the patent expi-
rations, and mature market７. The diversification strategy was employed by Pfizer, J&J, Eisai,
６ The paper does not consider which pattern is appropriate from the financial perspective. Comment（１９９５）,
however, considers the advantage of diversification and specialization from the follows: default rates capital
market transaction cost, increase the likelihood of takeover.
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Table ４ Management policy
Company motivation Policy
Pfizer to pursue cost reduction synergy effect,and the sales scale
seen M&A as a main growth
strategy
Gilead to fill the R&D gaps by external resources specialize in a specific field
J&J to expand the sales scale strengthen the presence in di-viserfication field
Astellas to optimum allocation of reources, improv-ing R&D capability
consentrate the management
resource to new medicine
business
Eisai to fill the R&D gaps in order to enhanceits R&D capability
strengthen the presence in di-
viserfication field in order to
expand the sales
Takeda to fill the R&D gaps in order to enhanceits R&D capability
keep high profitability by tech-
nical barries
DaiichiSankyo to fill the R&D gaps, diversifying profitsources
strengthen the presence in di-
viserfication field
Roche to fill the R&D gaps in order to enhanceits R&D capability specialize in a specific field
Merck to fill the R&D gaps in order to enhanceits R&D capability
strengthen the presence in di-
viserfication field
Novartis to fill the R&D gaps, diversifying profitsources
strengthen the presence in di-
viserfication field
Source: Based on annual reports of each company mentioned above.
Daiichi Sankyo, Merck, Novartis. For instance, Novartis is a company which diversified its
portfolio, and which has the leading position in pharmaceuticals, eye care, generic, vaccines,
over the counter medicines and animal health. This makes Novartis uniquely positioned to
capture opportunities across growing segments of the healthcare industry while mitigating
risks in other areas. The diversification has efforts to operation as efficiently as possible help
PCs to reduce unnecessary complexity in order to strengthen financial results（Kagono,２００４）.
As mentioned before, the paper defines diversification as a pattern that diversified
companies’portfolio based on chemical technology. In this case, PCs can maximize revenues
from their existing resources（technologies and commercialization channel）.
７ As most PCs focus their business on the field of lifestyle-related disease, which is in decline and where
competition is intensifying, they need to enter new fields.
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５. Conclusion
A common phenomenon was revealed here. That is, PCs step up utilization of ex-
ternal resources through licensing-in, cross-divisional collaboration and M&A, paving the
way for efficiency gains following the integration of technical of internal and external with
the aim of reinforcing innovation.
Distinct characteristics are revealed which consider the business portfolio and cor-
porate strategies of each company. Each company faces similar business challenges, which
include the patent expiration, and a decline in R&D productivity. The company taking spe-
cialization in its portfolio, aims to maintain and strengthen its positon in a given field. On the
other hand, the other company whose take diversification in its portfolio, may aim to offset a
decline in sales in the mature field（life-style related disease）.
Previous study suggests that diversification has risks of distribution effect, whereas
specialization has higher risks as it depends on the given business（Kagono, ２００４）. These
distinct strategies were taken to corporate policy, although not yet realized, and there is still
some uncertainty as to whether this will lead to the desired outcome and position, it pro-
vides an alternative mean of coping with the fast-changing business environment that PCs
face.
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